Although most TAM-targeted bi-specifics bind a second target on cancer cells or the TME, some use the second arm to enhance immune activation by engaging PD-1, PD-L1 or 4-1BB instead (Supplementary Table 1). The gene discussed is CD274; the disease is cancer.